On the basis of the effects of EMab-17 against OSCC cell lines, we explored whether EMab-17 shows similar anti-tumor activity in CRC cell lines with KRAS p.G13D mutations, as there are few effective treatments for patients with mCRC with KRAS mutated tumors. Here, KRAS is linked to neoplasm.